Outlook Therapeutics, Inc. (OTLK) Stock Analysis & Investment Frameworks

Outlook Therapeutics, Inc. (OTLK) stock analysis on Invetso. Review Outlook Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Outlook Therapeutics, Inc. Company Overview

Outlook Therapeutics, Inc. Key Financial Metrics

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated for its potential to treat wet age-related macular degeneration and other serious retinal diseases. The company has forged strategic collaboration and licensing agreements with several partners, including IPCA Laboratories Limited, Laboratorios Liomont, S.A. de C.V., BioLexis Pte. Ltd., and Zhejiang Huahai Pharmaceutical Co., Ltd. Incorporated in 2010, the firm was formerly known as Oncobiologics, Inc., changing its name to Outlook Therapeutics, Inc. in November 2018. Its corporate base is located in Iselin, New Jersey.

Outlook Therapeutics, Inc. Investment Frameworks

Invetso analyzes Outlook Therapeutics, Inc. (OTLK) across the following frameworks:

Explore More OTLK Research